Zomedica Q1 2024 GAAP EPS $(0.01) Down From $(0.007) YoY, Sales $6.262M Miss $8.184M Estimate
Portfolio Pulse from Benzinga Newsdesk
Zomedica reported Q1 2024 GAAP EPS of $(0.01), a 42.86% decrease from last year, with sales of $6.262M missing the $8.184M estimate, yet marking a 14.23% increase YoY.
May 09, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Zomedica's Q1 2024 earnings show a decrease in EPS and missed sales estimates, indicating potential short-term stock pressure.
The reported decrease in EPS and missed sales estimates are typically negative indicators for stock performance, suggesting potential short-term pressure on Zomedica's stock price. The miss on sales estimates by 23.48% and the decrease in EPS, despite a year-over-year sales increase, could lead to negative investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100